NewsEvents

Your Yourlocation: Home > Analysis of curative effect of budesonide dermoterol combined with tiotropium bromide(136310-93-5) on patients with severe chronic obstructive pulmonary disease

To investigate the clinical therapeutic effect of budesonide dermoterol combined with tiotropium bromide(136310-93-5) in patients with severe chronic obstructive pulmonary disease (COPD). 

Methods: 90 patients with severe COPD(45 cases) and the control group(45 cases) were randomly divided into two groups: routine treatment (conventional oxygen, anti-inflammatory, antispasmodic, asthma) on the basis of the test group using budesonide fu Trosin combined with tiotropium bromide(136310-93-5) inhalation, the control group was treated with budesonide dermostrol monotherapy, the treatment cycle of 6 months; the efficacy of the two groups of patients were compared analysis. 

Results: After 6 months of treatment. The blood gas and lung function of the patients in the experimental group were significantly higher than those in the control group (P <0.05). 

Conclusion: The results showed that the symptoms of the patients were significantly higher than those of the control group. The efficacy of tiotropium bromide(136310-93-5) combined with budesonide dermvotil in the treatment of severe COPD patients was greater than that of patients treated with budesonide dermotam alone, in patients with improved blood gas analysis, lung function, and dyspnea well, with the value of the promotion and application in clinical treatment.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved